Solid Tumor Clinical Trials in Scottsdale, Arizona

9 studies are recruiting for solid tumor in Scottsdale, Arizona right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Dabrafenib and/or Trametinib Rollover Study

   This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by…

   Stage

   Phase 4

   Ages

   18 to 100

   Site

   Honor Health Research Institute, Scottsdale, Arizona

   Locations

   34 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT03340506 on ClinicalTrials.gov

2. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Honor Health, Scottsdale, Arizona

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

3. Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

   GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Locations

   11 in total

   Run by

   Georgiamune Inc

   See if you can join NCT06425926 on ClinicalTrials.gov

4. Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

   This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-1965 as well as to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary an…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   CBCC Global Research Site 001, Scottsdale, Arizona

   Locations

   9 in total

   Run by

   Alyssum Therapeutics

   See if you can join NCT06234098 on ClinicalTrials.gov

5. A Study of PYX-201 in Advanced Solid Tumors

   The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Locations

   29 in total

   Run by

   Pyxis Oncology, Inc

   See if you can join NCT05720117 on ClinicalTrials.gov

6. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

   This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tum…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Scottsdale, Scottsdale, Arizona

   Locations

   15 in total

   Run by

   Tango Therapeutics, Inc.

   See if you can join NCT06810544 on ClinicalTrials.gov

7. Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

   This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab [Gazyva®] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned;…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Locations

   6 in total

   Run by

   Simcha IL-18, Inc.

   See if you can join NCT04787042 on ClinicalTrials.gov

8. A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

   Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research and Innovation Institute, Scottsdale, Arizona

   Locations

   4 in total

   Run by

   SparX Biotech(Jiangsu) Co., Ltd.

   See if you can join NCT06259552 on ClinicalTrials.gov

9. Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

   Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics [='PD']) * What does the body do to study drug (how processed in body (Pharmacokinetics [='PK']) - Safety Study drug by intravenous …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth, Scottsdale, Arizona

   Locations

   4 in total

   Run by

   Qualigen Theraputics, Inc.

   See if you can join NCT06086522 on ClinicalTrials.gov